Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2012

Aug 27, 2012

29977_dirs_2012-08-27_8bf5a0fc-2536-4d49-803e-b0afeb237e73.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-08-23

Reporting Person: McCorkle Douglas S (VP Controller and Asst Treasur)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-08-23 Common Stock M 5875.0 $30.63 Acquired 5875.0 Direct
2012-08-23 Common Stock F 1268.0 $141.85 Disposed 4607.0 Direct
2012-08-23 Common Stock F 2122.0 $141.85 Disposed 2485.0 Direct
2012-08-23 Common Stock M 9250.0 $21.25 Acquired 11735.0 Direct
2012-08-23 Common Stock F 1385.0 $141.85 Disposed 10350.0 Direct
2012-08-23 Common Stock F 3623.0 $141.85 Disposed 6727.0 Direct
2012-08-24 Common Stock S 200.0 $142.71 Disposed 6527.0 Direct
2012-08-24 Common Stock S 4178.0 $144.67 Disposed 2349.0 Direct
2012-08-24 Common Stock S 2149.0 $145.22 Disposed 200.0 Direct
2012-08-24 Common Stock S 200.0 $146.07 Disposed 0.0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-08-23 Non-Qualified Stock Option (right to buy) $21.25 M 9250.0 Disposed 2019-12-18 Common Stock (9250.0) Direct
2012-08-23 Non-Qualified Stock Option (right to buy) $30.63 M 5875.0 Disposed 2020-12-14 Common Stock (5875.0) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 4264.0 Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 200 shares of Company stock on August 24, 2012 at prices ranging from $142.55 to $142.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 4,178 shares of Company stock on August 24, 2012 at prices ranging from $144.11 to $144.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2012 at each separate price.

F4: Represents volume-weighted average price of sales of 2,149 shares of Company stock on August 24, 2012 at prices ranging from $145.00 to $145.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2012 at each separate price.

F5: Represents volume-weighted average price of sales of 200 shares of Company stock on August 24, 2012 at prices ranging from $146.00 to $146.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2012 at each separate price.

F6: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F7: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.